TARA Market Analysis
Wall Street coverage
third-party contextWall Street coverage
$25.71median target· current $3.87 (+564.3%)8 analysts
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
News & Sentiment
50 articles · sorted by datePage 1 of 3 · 50 total
Via 3rd party. Not a recommendation or advice by The Balanced Investor Club. See disclaimer.
Fundamentals
Updated daily after market closeP/E ratio—
EPS (TTM)$-1.370.0% YoY
Profit margin0.0%HEALTHCARE
Market cap$228.7MMicro cap
Valuation
- Forward P/E
- —
- PEG ratio
- —
- P/B
- 1.41
- P/S (TTM)
- —
- EV/EBITDA
- 0.74
Profitability & growth
- ROE (TTM)
- -45.8%
- Operating margin
- 0.0%
- Revenue growth YoY
- 0.0%
- Dividend yield
- —
- Beta
- 1.49
Last earnings
Aug 10, 2026 · Estimate $-0.33 · Reported $-0.36
Analyst estimate. Actual results often differ.
Ratios are point-in-time. Historical metrics — no guarantees about what comes next.
About Protara Therapeutics Inc
Company profileProtara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment of cancer and rare diseases. The company is headquartered in New York, New York.
Classification
- Sector
- Healthcare
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Country
- USA
- Currency
- USD
Company profile
- HQ
- 345 PARK AVENUE SOUTH, NEW YORK, NY
- Fiscal year end
- December
- Latest quarter
- Jun 30, 2026
Market cap$228.7M
Shares outstanding$59.1M
52W high$7.82
52W low$3.02
We're educators, not advisors. We don't make buy or sell recommendations under any circumstance. All content is for educational purposes. Past performance doesn't guarantee future results. Your decisions are your own. Disclaimer
Balanced Agent